FIELD: pharmacology.
SUBSTANCE: invention relates to application of cationic peptides for human skin melanoma cells death induction selected from the group consisting of R8K4K2KAC-NH2, K8K4K2KAC-NH2, (RRRKK)2KKKAC-NH2, (K)4(K)2KAC-NH2 and Mir-KRPARPAR-NH2.
EFFECT: human skin melanoma cells death induction and reduced side effects on normal cells.
2 ex, 4 dwg, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
LABELLED DENDRIMER PEPTIDES | 2016 |
|
RU2611399C1 |
MEAN FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS TO CELLS OF MAMMALS | 2014 |
|
RU2572575C1 |
PEPTIDES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2020 |
|
RU2771605C2 |
CELL PRODUCT FOR LOADING AND ACTIVATION OF HUMAN DENDRITE CELLS | 2019 |
|
RU2714208C1 |
COMPOSITION INHIBITING EXPRESSION OF INTERLEUKIN-4 AND INTERLEUKIN-13 GENES FOR THERAPY OF ALLERGIC RHINITIS | 2018 |
|
RU2710895C1 |
CATIONIC BRANCHED PEPTIDE FOR RESPIRATORY VIRUS INHIBITION | 2022 |
|
RU2810986C2 |
POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
HUMAN SKIN MELANOMA CELL LINE mel-Alx-LP | 2022 |
|
RU2796357C1 |
Authors
Dates
2017-05-23—Published
2016-08-02—Filed